These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37137525)

  • 1.
    Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
    Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
    Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
    Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
    J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the likelihood of a
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
    J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
    Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Pathogenic Germline
    Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
    Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
    Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
    BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.